THE US Food and Drug Administration has approved the Sydney-based manufacturing facility of ASX-listed Pharmaxis, which yesterday confirmed it would relaunch its Aridol product into the North American market.
Aridol was first approved by the FDA in 2011 to identify bronchial hyperresponsiveness as an aid to diagnosing asthma, but withdrawn from the market in 2013 as part of a corporate restructuring.
US sales will resume by Dec through Methaparm Inc, which is Pharmaxis' exclusive distributor in North America.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Aug 18
